Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter

American Journal of Cardiology

Volumn 115, Issue 5, 2015, Pages 635-640

  Zylla, Maura M ^a   Pohlmeier, Mara ^a   Hess, Alexander ^a   Mereles, Derliz ^a   Kieser, Meinhard ^b   Bruckner, Thomas ^b   Scholz, Eberhard ^a   Zitron, Edgar ^a   Schweizer, Patrick A ^a   Katus, Hugo A ^a   Thomas, Dierk ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; RIVAROXABAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CHAD; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG SAFETY; FEMALE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT ATRIUM; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT ATRIUM; HEART SIZE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERNATIONAL NORMALIZED RATIO; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ARRHYTHMIAS, CARDIAC; CARDIOVERSION; COHORT ANALYSIS; COMPLICATION; MIDDLE AGED; PREVALENCE; THROMBOSIS;

AGED; ANTICOAGULANTS; ARRHYTHMIAS, CARDIAC; BENZIMIDAZOLES; BETA-ALANINE; COHORT STUDIES; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PHENPROCOUMON; PREVALENCE; THIOPHENES; THROMBOSIS; VITAMIN K;

EID: 84923003304     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2014.12.016     Document Type: Article

References (23)

1. K.E. Airaksinen, T. Gronberg, I. Nuotio, M. Nikkinen, A. Ylitalo, F. Biancari, and J.E. Hartikainen Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study J Am Coll Cardiol 62 2009 1187 1192
2. A.Z. Arnold, M.J. Mick, R.P. Mazurek, F.D. Loop, and R.G. Trohman Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter J Am Coll Cardiol 19 1992 851 855
3. B. Lown, M.G. Perlroth, S. Kaidbey, T. Abe, and D.E. Harken "Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients N Engl J Med 269 1963 325 331
4. C.R. Asher, A.L. Klein The ACUTE trial Transesophageal echocardiography to guide electrical cardioversion in atrial fibrillation. Assessment of Cardioversion Using Transesophageal Echocardiography Cleve Clin J Med 69 2002 713 718
5. R.A. Grimm, W.J. Stewart, K. Arheart, J.D. Thomas, and A.L. Klein Left atrial appendage "stunning" after electrical cardioversion of atrial flutter: an attenuated response compared with atrial fibrillation as the mechanism for lower susceptibility to thromboembolic events J Am Coll Cardiol 29 1997 582 589
6. R. Nagarakanti, M.D. Ezekowitz, J. Oldgren, S. Yang, M. Chernick, T.H. Aikens, G. Flaker, J. Brugada, G. Kamensky, A. Parekh, P.A. Reilly, S. Yusuf, and S.J. Connolly Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion Circulation 123 2011 131 136
7. European Heart Rhythm Association European Association for Cardio-Thoracic Surgery A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, S. Ernst, I.C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S.H. Hohloser, P. Kolh, J.Y. Le Heuzey, P. Ponikowski, F.H. Rutten ESC Committee for Practice Guidelines Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Europace 12 2010 1360 1420
8. A.J. Camm, G.Y. Lip, R. De Caterina, I. Savelieva, D. Atar, S.H. Hohnloser, G. Hindricks, P. Kirchhof ESC Committee for Practice Guidelines-CPG 2012 Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association Europace 14 2012 1385 1413
9. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini, S.D. Berkowitz, K.A. Fox, R.M. Califf ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
10. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, H.R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton, J.A. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B.J. Gersh, S. Golitsyn, S. Goto, A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis, J.L. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W. Verheugt, J. Zhu, L. Wallentin ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
11. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, L. Wallentin RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
12. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, A.L. Waldo, M.D. Ezekowitz, J.I. Weitz, J. Špinar, W. Ruzyllo, M. Ruda, Y. Koretsune, J. Betcher, M. Shi, L.T. Grip, S.P. Patel, I. Patel, J.J. Hanyok, M. Mercuri, E.M. Antman ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
13. S. Lydersen, M.W. Fagerland, and P. Laake Recommended tests for association in 2 x 2 tables Stat Med 28 2009 1159 1175
14. C.R. Mehta, and N.R. Patel Exact logistic regression: theory and examples Stat Med 14 1995 2143 2160
15. 2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion (from the ACUTE Trial Substudy) Am J Cardiol 110 2012 222 226
16. G. Flaker, R.D. Lopes, S.M. Al-Khatib, A.G. Hermosillo, S.H. Hohnloser, B. Tinga, J. Zhu, P. Mohan, D. Garcia, J. Bartunek, D. Vinereanu, S. Husted, V.P. Harjola, M. Rosenqvist, J.H. Alexander, C.B. Granger ARISTOTLE Committees and Investigators Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) J Am Coll Cardiol 63 2014 1082 1087
17. J.P. Piccini, S.R. Stevens, Y. Lokhnygina, M.R. Patel, J.L. Halperin, D.E. Singer, G.J. Hankey, W. Hacke, R.C. Becker, C.C. Nessel, K.W. Mahaffey, K.A. Fox, R.M. Califf, G. Breithardt ROCKET AF Steering Committee & Investigators Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J Am Coll Cardiol 61 2013 1998 2006
18. A. Yadlapati, C. Groh, and R. Passman Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter Am J Cardiol 113 2014 1362 1363
19. R. Cappato, M.D. Ezekowitz, A.L. Klein, A.J. Camm, C.S. Ma, J.Y. Le Heuzey, M. Talajic, M. Scanavacca, P.E. Vardas, P. Kirchhof, M. Hemmrich, V. Lanius, I.L. Meng, P. Wildgoose, M. van Eickels, S.H. Hohnloser on behalf of the X-VeRT Investigators Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation Eur Heart J 35 2014 3346 3355
20. D.Y. Leung, I.W. Black, G.B. Cranney, A.P. Hopkins, and W.F. Walsh Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation J Am Coll Cardiol 24 1994 755 762
21. K. Kupczynska, J.D. Kasprzak, B. Michalski, and P. Lipiec Prognostic significance of spontaneous echocardiographic contrast detected by transthoracic and transesophageal echocardiography in the era of harmonic imaging Arch Med Sci 9 2013 808 814
22. M. Zabalgoitia, J.L. Halperin, L.A. Pearce, J.L. Blackshear, R.W. Asinger, and R.G. Hart Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators J Am Coll Cardiol 31 1998 1622 1626
23. H.1 Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, P. Sinnaeve, A.J. Camm, P. Kirchhof European Heart Rhythm Association European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651